{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:37:33Z","timestamp":1792237053454,"version":"4.4.0"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T00:00:00Z","timestamp":1253577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Numerous cocktails using concurrent administration of several cytochrome P450 (CYP) isoform\u2010selective probe drugs have been reported to investigate drug\u2013drug interactions<jats:italic>in vivo<\/jats:italic>.<\/jats:p><jats:p>\u2022\u2003This approach has several advantages: characterize the inhibitory or induction potential of compounds in development toward the CYP enzymes identified<jats:italic>in vitro<\/jats:italic>in an<jats:italic>in vivo<\/jats:italic>situation, assess several enzymes in the same trial, and have complete<jats:italic>in vivo<\/jats:italic>information about potential CYP\u2010based drug interactions.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003This study describes a new cocktail containing five probe drugs that has never been published.<\/jats:p><jats:p>\u2022\u2003This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold>To assess the pharmacokinetics (PK) of selective substrates of CYP1A2 (caffeine), CYP2C9 (S\u2010warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol) and CYP3A (midazolam) when administered orally and concurrently as a cocktail relative to the drugs administered alone.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold>This was an open\u2010label, single\u2010dose, randomized, six\u2010treatment six\u2010period six\u2010sequence William's design study with a wash\u2010out of 7 or 14 days. Thirty healthy male subjects received 100\u2003mg caffeine, 100\u2003mg metoprolol, 0.03\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>midazolam, 20\u2003mg omeprazole and 10\u2003mg warfarin individually and in combination (cocktail). Poor metabolizers of CYP2C9, 2C19 and 2D6 were excluded. Plasma samples were obtained up to 48\u2003h for caffeine, metoprolol and omeprazole, 12\u2003h for midazolam, 312\u2003h for warfarin and the cocktail. Three different validated liquid chromatography tandem mass spectrometry methods were used. Noncompartmental PK parameters were calculated. Log\u2010transformed<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, AUC<jats:sub>last<\/jats:sub>and AUC for each analyte were analysed with a linear mixed effects model with fixed term for treatment, sequence and period, and random term for subject within sequence. Point estimates (90% CI) for treatment ratios (individual\/cocktail) were computed for each analyte<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, AUC<jats:sub>last<\/jats:sub>and AUC.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>There was no PK interaction between the probe drugs when administered in combination as a cocktail, relative to the probes administered alone, as the 90% CI of the PK parameters was within the prespecified bioequivalence limits of 0.80, 1.25.<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>The lack of interaction between probes indicates that this cocktail could be used to evaluate the potential for multiple drug\u2013drug interactions<jats:italic>in vivo<\/jats:italic>.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03548.x","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T14:24:01Z","timestamp":1253629441000},"page":"928-935","source":"Crossref","is-referenced-by-count":129,"title":["Pharmacokinetic assessment of a five\u2010probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A"],"prefix":"10.1111","volume":"68","author":[{"given":"Sandrine","family":"Turpault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Brian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Van Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Poitiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Donazzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Boulenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00229-7"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100187"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.105.005272","article-title":"Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers","volume":"33","author":"Tomalik\u2010Scharte D","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00781.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003261333"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/mi.3.4.194"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP39037"},{"key":"e_1_2_6_9_2","unstructured":"Efficacy working party: questions and answers on the use of Cocktail studies for investigatingin vivodrug interaction potential. EMEA\/CHMP\/EWP\/490784\/2007."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00410.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050482"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315140"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90719-2"},{"key":"e_1_2_6_14_2","first-page":"1105","article-title":"Inhibitory effect of omeprazole on the metabolism of midazolam in vitro","volume":"40","author":"Li G","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05112.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-199912000-00007"},{"key":"e_1_2_6_17_2","first-page":"1191","article-title":"In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s","volume":"25","author":"Prueksaritanont T","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109519"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03548.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03548.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:49:29Z","timestamp":1739350169000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03548.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03548.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03548.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}